Suppr超能文献

miR-20a 通过调节启动子活性调控骨肉瘤细胞中 FAS 的表达,可作为治疗靶点抑制肺转移。

miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.

机构信息

Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Immunotherapy Institute, Fujian Medical University, University Town, Fuzhou, China.

出版信息

Mol Cancer Ther. 2018 Jan;17(1):130-139. doi: 10.1158/1535-7163.MCT-17-0042. Epub 2017 Oct 27.

Abstract

The metastatic potential of osteosarcoma cells is inversely correlated to cell surface FAS expression. Downregulation of FAS allows osteosarcoma cells to escape FAS ligand-mediated apoptosis when they enter a FAS ligand-positive microenvironment such as the lung. We have previously demonstrated that miR-20a, encoded by the miR-17-92 cluster, downregulates FAS expression in osteosarcoma. We further demonstrated an inverse correlation between FAS expression and miR-20a expression. However, the mechanism of regulation by miR-20a was still unclear. The purpose of the current study was to evaluate the mechanism of regulation by miR-20a and test the effect of targeting miR-20a We investigated whether miR-20a's downregulation of was mediated by binding to the 3'-untranslated region (3'-UTR) of mRNA with the consequent induction of mRNA degradation or translational suppression. We identified and mutated two miR-20a binding sites on the mRNA 3'-UTR. Using luciferase reporter assays, we demonstrated that miR-20a did not bind to either the wild-type or mutated 3'-UTR. In contrast, overexpression of miR-20a resulted in downregulation of promoter activity. Similarly, the inhibition of miR-20a increased promoter activity. The critical region identified on the promoter was between -240 bp and -150 bp. Delivery of anti-miR-20a using nanoparticles in mice with established osteosarcoma lung metastases resulted in upregulation of and tumor growth inhibition. Taken together, our data suggest that miR-20a regulates expression through the modulation of the promoter and that targeting miR-20a using anti-miR-20a has therapeutic potential. .

摘要

骨肉瘤细胞的转移潜能与细胞表面 Fas 表达呈负相关。Fas 表达下调使骨肉瘤细胞在进入 Fas 配体阳性微环境(如肺)时能够逃避 Fas 配体介导的细胞凋亡。我们之前已经证明,miR-17-92 簇编码的 miR-20a 下调骨肉瘤细胞中 Fas 的表达。我们进一步证明 Fas 表达与 miR-20a 表达呈负相关。然而,miR-20a 的调控机制仍不清楚。本研究的目的是评估 miR-20a 的调控机制,并测试靶向 miR-20a 的效果。我们研究了 miR-20a 是否通过与 mRNA 的 3'-非翻译区(3'-UTR)结合来下调 ,从而诱导 mRNA 降解或翻译抑制。我们鉴定并突变了 mRNA 3'-UTR 上的两个 miR-20a 结合位点。通过荧光素酶报告基因检测,我们证明 miR-20a 不能与野生型或突变型 3'-UTR 结合。相反,miR-20a 的过表达导致 启动子活性下调。同样,miR-20a 的抑制增加了 启动子活性。在 启动子上鉴定的关键区域位于-240 bp 和-150 bp 之间。在已建立骨肉瘤肺转移的小鼠中,使用纳米颗粒递送抗 miR-20a,导致 上调和肿瘤生长抑制。综上所述,我们的数据表明,miR-20a 通过调节 启动子来调节 的表达,并且使用抗 miR-20a 靶向 miR-20a 具有治疗潜力。

相似文献

引用本文的文献

2
Delivery of miRNAs Using Nanoparticles for the Treatment of Osteosarcoma.利用纳米颗粒递送 miRNA 治疗骨肉瘤。
Int J Nanomedicine. 2024 Aug 22;19:8641-8660. doi: 10.2147/IJN.S471900. eCollection 2024.
5
miR-aculous new avenues for cancer immunotherapy.miR- 开辟癌症免疫治疗的新途径。
Front Immunol. 2022 Sep 28;13:929677. doi: 10.3389/fimmu.2022.929677. eCollection 2022.

本文引用的文献

3
Oligonucleotide Therapies: The Past and the Present.寡核苷酸疗法:过去与现在。
Hum Gene Ther. 2015 Aug;26(8):475-85. doi: 10.1089/hum.2015.070. Epub 2015 Aug 3.
6
Non-viral vectors for gene-based therapy.基于基因治疗的非病毒载体。
Nat Rev Genet. 2014 Aug;15(8):541-55. doi: 10.1038/nrg3763. Epub 2014 Jul 15.
7
8
CD95 is part of a let-7/p53/miR-34 regulatory network.CD95 是 let-7/p53/miR-34 调控网络的一部分。
PLoS One. 2012;7(11):e49636. doi: 10.1371/journal.pone.0049636. Epub 2012 Nov 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验